PubMed_ArguminSci  

PubMed:27783941 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 98-180 DRI_Challenge denotes Malignant brain tumors are the leading cause of cancer-related deaths in children.
T2 181-309 DRI_Background denotes Primitive neuroectodermal tumors of the CNS (CNS-PNETs) are particularly aggressive embryonal tumors of unknown cellular origin.
T3 310-564 DRI_Background denotes Recent genomic studies have classified CNS-PNETs into molecularly distinct subgroups that promise to improve diagnosis and treatment; however, the lack of cell- or animal-based models for these subgroups prevents testing of rationally designed therapies.
T4 565-595 DRI_Outcome denotes Here, we show that a subset of
T5 629-760 DRI_Outcome denotes precursor cell (OPC) markers OLIG2 and SOX10 with coincident activation of the RAS/MAPK (mitogen-activated protein kinase) pathway.
T6 761-878 DRI_Outcome denotes Modeling NRAS activation in embryonic OPCs generated malignant brain tumors in zebrafish that closely mimic the human
T7 909-960 DRI_Outcome denotes subgroup by histology and comparative oncogenomics.
T8 961-1134 DRI_Outcome denotes The zebrafish CNS-PNET model was used to show that MEK inhibitors selectively eliminate Olig2(+)/Sox10(+) CNS-PNET tumors in vivo without impacting normal brain development.
T9 1135-1233 DRI_Approach denotes Thus, MEK inhibitors represent a promising rationally designed therapy for children afflicted with
T10 1264-1265 DRI_Approach denotes .